The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2024

Filed:

Dec. 21, 2020
Applicant:

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Patrick Koenig, San Francisco, CA (US);

Chingwei Vivian Lee, Foster City, CA (US);

Karthikan Rajagopal, South San Francisco, CA (US);

Amin Famili, South San Francisco, CA (US);

Germaine Fuh, Pacifica, CA (US);

Assignee:

Genentech, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C40B 30/04 (2006.01); A61K 39/395 (2006.01); A61K 47/34 (2017.01); A61K 47/60 (2017.01); A61K 47/61 (2017.01); C07K 14/475 (2006.01); C07K 16/22 (2006.01); C07K 16/44 (2006.01); C07K 16/46 (2006.01); C12N 15/10 (2006.01); C12N 15/115 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/61 (2017.08); A61K 39/3955 (2013.01); A61K 47/34 (2013.01); A61K 47/60 (2017.08); C07K 14/475 (2013.01); C07K 16/22 (2013.01); C07K 16/44 (2013.01); C07K 16/468 (2013.01); C12N 15/1037 (2013.01); C12N 15/115 (2013.01); C40B 30/04 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2318/20 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C12N 2310/16 (2013.01);
Abstract

The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.


Find Patent Forward Citations

Loading…